Publications by authors named "Naomi Onda"

Background: Acute exacerbation (AEx) of interstitial pneumonia is the most common lethal adverse event related to the pharmacological treatment of patients with lung cancer complicated with interstitial pneumonia. Although small cell lung cancer (SCLC) is linked to poor prognosis, it exhibits good response to chemotherapy. Few previous research studies have investigated the safety and efficacy of treatment for advanced SCLC complicated with idiopathic interstitial pneumonia (IIP).

View Article and Find Full Text PDF
Article Synopsis
  • * After treatment, he developed various symptoms, including skin purpuras, joint swelling, abdominal pain, diarrhea, and acute kidney injury, leading to the diagnosis of IgA vasculitis.
  • * The patient's symptoms improved after stopping pembrolizumab and starting glucocorticoids, highlighting the need for careful monitoring for immune-related adverse events during similar cancer treatments.
View Article and Find Full Text PDF

Osimertinib induces a marked response in non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) gene mutations. However, acquired resistance to osimertinib remains an inevitable problem. In this study, we aimed to investigate osimertinib-resistant mechanisms and evaluate the combination therapy of afatinib and chemotherapy.

View Article and Find Full Text PDF

Introduction: A neurotrophic tropomyosin receptor kinase (NTRK)-tyrosine kinase inhibitor (TKI) has shown dramatic efficacy against malignant tumors harboring an NTRK fusion gene. However, almost all tumors eventually acquire resistance to NTRK-TKIs.

Method: To investigate the mechanism of resistance to NTRK-TKIs, we established cells resistant to three types of NTRK-TKIs (larotrectinib, entrectinib, and selitrectinib) using KM12 colon cancer cells with a TPM3-NTRK1 rearrangement.

View Article and Find Full Text PDF
Article Synopsis
  • Amrubicin (AMR) is an effective drug for small-cell lung cancer (SCLC), but it can cause significant side effects, especially at a standard dose of 40 mg/m.
  • A study analyzing patient data from Nippon Medical School Hospital evaluated the safety and efficacy of AMR at varying doses (40, 35, and 30 mg/m) in patients with relapsed SCLC.
  • Results suggested that lower doses (30-35 mg/m) resulted in less severe side effects without sacrificing effectiveness, indicating that these lower doses could be a better treatment option for patients, particularly older ones.
View Article and Find Full Text PDF

Crystal-storing histiocytosis (CSH) is an uncommon finding in lymphoplasmacytic disorders that presents histiocytes with abnormal intralysosomal accumulations of immunoglobulin light chains as crystals of unknown etiology. A 38-year-old woman with antiphospholipid syndrome had a surgical lung biopsy because of multiple lung mass lesions. In a right middle lobe lesion, lymphoplasmacytic cells had a monocytoid appearance, destructive lymphoepithelial lesions, and positive immunoglobulin heavy chain (IGH) gene rearrangements.

View Article and Find Full Text PDF

Pulmonary hypertension is a poor prognostic factor in patients with interstitial lung disease. No established treatment exists for pulmonary hypertension secondary to interstitial pneumonia. We describe the case of an 81-year-old woman with idiopathic pulmonary fibrosis (IPF), who was admitted to our hospital due to aggravation of dyspnea and decreased oxygen saturation, as well as onset of orthopnea and rapidly progressing edema.

View Article and Find Full Text PDF